BioSpace News Archive

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal system growth.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today presented new data on patient-preferred on-demand treatment measures in hereditary angioedema (HAE), and on the effects that the disease has on quality of life for people living with HAE, at the 2022 HAEi Global Leadership Workshop in Frankfurt, Germany.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to a new employee as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

Everest Medicines Limited (HKEX 1952.HK, “Everest Medicines”, or the “Company”) announced today that the Department of Health of the Hong Kong Special Administrative Region, China, has approved a New Drug Application (NDA) for XERAVA®.

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company’s shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”).

Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing, and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), today announced that Neil Clendeninn, MD, PhD, joined as Chief Medical Officer.

Avirmax Inc.(www.avirmax.com) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,453,869, which is directed to the composition and methods related to the use and administration of catalysis deactivated angiotensin-converting enzyme 2 (ACE2) for preventing SARS-COV-1 and SARS-COV-2 infection.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Blocking the action of calcium signals in immune cells suppresses the most common form of asthma, but without compromising the body’s defenses against flu viruses, a new study finds.

Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME) is pleased to announce that the Company’s securityholders have approved its plan to become a Delaware corporation (the “Redomicile”) at the special meeting of Zymeworks securityholders (the “Special Meeting”) held in Vancouver, BC, on October 7, 2022.